View clinical trials related to Neoplasms.
Filter by:A Phase 1/2 Multicenter, Open-Label, Dose-Escalation and Expansion Study of TTX MC138 in Subjects with Advanced Solid Tumors
Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality
Assessment of the association between human papillomavirus vaccination (HPV) and recurrences of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) in women undergoing conization.
The objective of this observational study is to introduce a patient navigation system within the breast cancer unit at Hospital Central de Maputo (MOZ) and gather data to assess the efficacy of patient navigation in enhancing oncological outcomes among this patient cohort. The primary inquiries it seeks to address are as follows: - Can patient navigation reduce the duration (in days) between patient admission and the commencement of treatment? - Does patient navigation influence overall survival rates when juxtaposed with historical cohorts from the local setting? Participants will receive continuous support from a patient navigator starting from admission until the initiation of any oncological treatment.
This single-armed, open, phase I study was designed to evaluate the safety and tolerance of ReT01 ACT injection in the treatment of advanced solid tumors. The phase I clinical trial is expected to be finished in 1 year.
Cancer treatment in children is very effective, but unfortunately has side effects - unwanted, bad impact. Some drugs that are given during cancer treatment, in addition to their good effect, can affect the heart badly and can lower the physical activity tolerance, such as climbing stairs, fast walking, running, exercise. Physical activity is very important for the proper growth and development of children and future adults. Heart is an important organ pumping the blood around the body and its good function is one of the key determinants of physical activity level in humans. The goal of this study is to is to find what impacts physical activity level in children treated for cancer with treatment methods that may be toxic to the heart to learn about influence of this treatment on the physical activity level of these children. The main questions this study aims to answer are: - Do children after cancer treatment involving heart toxic treatment methods present lower level of daily physical activity in comparison to the children treated with different methods? - Is the level of physical activity related to the heart toxic treatment, or other such as exercise capacity (measured physical strength on the treadmill or standing bike), quality of life, lifestyle, social and demographic factors, body type as well as the knowledge about positive impact of physical activity, efficacy, and motivation to physical activity? Participants will: - fill in the questionnaire, - perform an exercise test on the treadmill or standing bike (to measure exercise capacity), - perform ALPHA test (physical fitness test) consisting of some simple exercise like jumping, running etc., - be measured and weighted, - be measured by the hand-grip test with the hand dynamometer machine, - wear activity-tracker band for 14 days, - be examined by the ultrasound of the heart (echocardiography). Researchers will compare 144 children treated with heart toxic methods for cancer to 144 children treated for cancer with non-toxic methods. The children will be aged 8-18 years old and will be 1-5 years after treatment for cancer. The researchers believe that finding what influences physical activity level in children after cancer treatment with heart toxic methods may - make the therapy for cancer in children better, with less side effects - by that, can cause increase in the physical activity and ensure better growth and health for these children in the future.
The study is being conducted to evaluate the preference, and safety of HHPG-19K Injection and Auto-HHPG-19K Injection in Prevention of chemotherapy-related moderate to severe neutropenia of Patients with nonmyeloid malignancies.
The purpose of this study is to find the biggest dose of HTR2 T cells that is safe, to see how long these cells last in the body, to learn the side effects, and to see if these cells are able to fight and kill HER2 expressing breast cancer. Patients eligible for this study have metastatic breast cancer that has HER2 expression and has progressed on at least one line of therapy. This is a gene transfer research study using special immune cells called T cells. T cells are a type of white blood cell that helps the body recognize and fight cancer cells. The body has different ways of fighting diseases and no single way seems perfect for fighting cancer. This research combines two different ways of fighting cancer: antibodies and T cells. Antibodies are proteins that protect the body from infectious disease and possibly cancer. T cells, or T lymphocytes, are special blood cells that can kill other cells, including tumor cells. Both antibodies and T cells have shown promise treating cancer but have not been strong enough to cure most patients. Previous research has found that investigators can put genes into T cells that helps them recognize cancer cells and kill them. Investigators now want to see if by putting a new gene in those T cells to help recognize breast cancer cells expressing HER2 can kill the cancer cells. In clinical trials for various cancer types that express HER2, our center engineered a CAR that recognizes HER2 and put this CAR into patients own T cells and gave them back. Investigators saw that the cells did grow and patients did tolerate and respond to the treatment. Investigators will add a gene to the HER2 recognizing CAR T cells that will improve the T cells function. Investigators know that some immune cells in the body can lower T cells ability to kill cancer cells. Investigators have identified an antibody that will inactivate those immune suppressive cells thereby allowing T cells to survive better to recognize and kill cancer cells. This antibody targets the Trail-R2 receptor and is referred to as TR2. Also, investigators know that T cells need the support of cytokines to perform their immune functions. There is evidence showing that the addition of interleukin 15 (IL15) enhances CAR T cells ability to kill cancer cells. As a result, investigators also added IL15 to the HER2 and TR2 targeting CAR T cells (HTR2 T cells). The HTR2 T cells are an investigational product not approved by the Food and Drug Administration.
Less than 15% of Chinese Americans complete advance directives. That is less than half of the 37% completion rate in the US general population. This disparity in the use of advance care planning between White Americans and Chinese Americans may extend to disparities in end-of-life care. To address such disparities in end-of-life care, we will develop and assess the acceptability of a culturally tailored resilience-building intervention to help Chinese Americans with cancer or heart disease and their family caregivers engage in advance care planning discussions.
This trial is to investigate the safety, efficacy of iNK in subjects with solid tumor. It is a dose escalation and extension trial.